Daniel Baram1, Ruel B Garcia, Paul S Richman. 1. Division of Pulmonary/Critical Care, Stony Brook University, T-17, 040 HSC, Stony Brook, NY 11794-8172, USA. dbaram@notes.cc.sunysb.edu
Abstract
STUDY OBJECTIVE: To determine the extent to which rapid on-site cytologic evaluation (ROSE) of transbronchial needle aspiration (TBNA) samples can safely and cost-effectively reduce the need for additional biopsy during bronchoscopy. SETTING: University Hospital in Long Island, NY. PATIENT AND METHODS: Forty-four bronchoscopies with TBNA, most of which utilized ROSE, were evaluated prospectively. The number and types of biopsies performed during each procedure were compared to a preprocedural algorithm to determine the impact of knowing ROSE results during the procedure. Bronchoscopies performed with and without ROSE were compared, as were bronchoscopies with diagnostic and nondiagnostic ROSE results. A cost analysis was performed comparing the Medicare reimbursement for ROSE to the savings of deferring multiple biopsies. RESULTS: Thirty-two bronchoscopies were performed with ROSE; 12 were performed without ROSE. Fewer biopsies were performed during bronchoscopies utilizing ROSE. Diagnostic yield, TBNA sensitivity and accuracy, and procedural time were similar between these two groups. CONCLUSIONS: ROSE during TBNA allows for deferring additional biopsy without loss in diagnostic yield, likely lowers procedural risk, and is cost-effective.
STUDY OBJECTIVE: To determine the extent to which rapid on-site cytologic evaluation (ROSE) of transbronchial needle aspiration (TBNA) samples can safely and cost-effectively reduce the need for additional biopsy during bronchoscopy. SETTING: University Hospital in Long Island, NY. PATIENT AND METHODS: Forty-four bronchoscopies with TBNA, most of which utilized ROSE, were evaluated prospectively. The number and types of biopsies performed during each procedure were compared to a preprocedural algorithm to determine the impact of knowing ROSE results during the procedure. Bronchoscopies performed with and without ROSE were compared, as were bronchoscopies with diagnostic and nondiagnostic ROSE results. A cost analysis was performed comparing the Medicare reimbursement for ROSE to the savings of deferring multiple biopsies. RESULTS: Thirty-two bronchoscopies were performed with ROSE; 12 were performed without ROSE. Fewer biopsies were performed during bronchoscopies utilizing ROSE. Diagnostic yield, TBNA sensitivity and accuracy, and procedural time were similar between these two groups. CONCLUSIONS: ROSE during TBNA allows for deferring additional biopsy without loss in diagnostic yield, likely lowers procedural risk, and is cost-effective.
Authors: Sinchita Roy-Chowdhuri; Hui Chen; Rajesh R Singh; Savitri Krishnamurthy; Keyur P Patel; Mark J Routbort; Jawad Manekia; Bedia A Barkoh; Hui Yao; Sharjeel Sabir; Russell R Broaddus; L Jeffrey Medeiros; Gregg Staerkel; John Stewart; Rajyalakshmi Luthra Journal: Mod Pathol Date: 2017-01-13 Impact factor: 7.842
Authors: Matthew J Bott; Bryce James; Brian T Collins; Benjamin A Murray; Varun Puri; Daniel Kreisel; A Sasha Krupnick; G Alexander Patterson; Stephen Broderick; Bryan F Meyers; Traves D Crabtree Journal: Ann Thorac Surg Date: 2015-05-20 Impact factor: 4.330
Authors: Mohammed Al-Jaghbeer; Mathew Marcus; Martin Durkin; Franklin R McGuire; Imran H Iftikhar Journal: Ther Adv Respir Dis Date: 2016-03-04 Impact factor: 4.031
Authors: Alberto Fernández-Villar; Maribel Botana; Virginia Leiro; Ana González; Cristina Represas; Alberto Ruano-Raviña Journal: BMC Pulm Med Date: 2010-04-28 Impact factor: 3.317